Breaking News Instant updates and real-time market news.

TEVA

Teva

$16.90

0.02 (0.12%)

10:11
04/09/18
04/09
10:11
04/09/18
10:11

Teva closing Israeli plant after failing to find buyer, Reuters reports

Teva is closing a plant in Israel's Ashdod in March 2019 after failing to find a buyer for the unprofitable facility, Reuters reports. Half of the factory's 175 workers will lose their jobs in the coming months with the rest continuing to work until the plant closes, Teva says. "The Teva Ashdod plant is part of the reorganization process being carried out in Israel and around the world in order to reduce the cost base due to the heavy debt the company faces and the complex business circumstances it is dealing with," Teva said in an emailed statement. Reference Link

  • 18

    May

  • 16

    Jun

TEVA Teva
$16.90

0.02 (0.12%)

02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
02/21/18
DBAB
02/21/18
NO CHANGE
Target $20
DBAB
Hold
Deutsche sees rifamycin as possible long-term threat to Valeant
The outlook for Valeant Pharmaceuticals' (VRX) Xifaxan, which represents 13% of the company's revenue, improved last year following safety issues for competitor Viberzi and delays for generic challenger Teva (TEVA), Deutsche Bank analyst Gregg Gilbert tells investors in a research note. More recently, the analyst notes, questions have been raised as to whether Cosmo's rifamycin could pose a threat to Xifaxan, either in the near term from off-label prescribing for irritable bowel syndrome with diarrhea, or longer term if eventually approved for IBS-D. After due diligence, Gilbert believes rifamycin could potentially be a longer-term threat to Xifaxan if it works for IBS-D, but he does not see "material risk" from off-label use in the interim. His model continues to assume mid-single digit Xifaxan sales growth for several years and a generic cliff in 2025. The analyst keeps a Hold rating on Valeant with a $20 price target.
03/20/18
JEFF
03/20/18
INITIATION
Target $19
JEFF
Hold
Teva resumed with a Hold at Jefferies
Jefferies analyst David Steinberg resumed coverage of Teva Pharmaceutical with a Hold rating and $19 price target. The analyst sees "headwinds on multiple fronts" and believes the positive outlook for Austedo and fremanezumab is priced in with the shares trading at 10 times 2020 consensus EBITDA.
03/26/18
RBCM
03/26/18
NO CHANGE
Target $16
RBCM
Sector Perform
RBC Capital concerned with 'overly ambitious' consensus assumptions for Teva
RBC Capital analyst Randall Stanicky lowered his price target on Teva to $16 from $18, saying that his own model contrasts with "overly optimistic" consensus regarding the P&L assumptions in the company's Branded segment. Specifically, the analyst is concerned with the rising generic competition for Teva's Copaxone as well as fremanezumab, which he expects to miss the June 16 PDUFA "given Celltrion's outstanding Warning Letter" while lowering his peak sales projections by $200M to $1B. Stanicky keeps his Sector Perform rating on Teva, adding that the multi-year turnaround investment thesis on the stock is not supported at this point.

TODAY'S FREE FLY STORIES

ANAB

AnaptysBio

$68.73

0.8 (1.18%)

05:03
11/21/18
11/21
05:03
11/21/18
05:03
Initiation
AnaptysBio initiated  »

AnaptysBio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

DexCom

$119.89

-1.34 (-1.11%)

, GOOG

Alphabet

$1,026.00

7 (0.69%)

05:01
11/21/18
11/21
05:01
11/21/18
05:01
Hot Stocks
DexCom, Alphabet's Verily amend collaboration and license agreement »

DexCom (DXCM) and Verily,…

DXCM

DexCom

$119.89

-1.34 (-1.11%)

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

  • 03

    Mar

ADI

Analog Devices

$89.12

3.57 (4.17%)

04:55
11/21/18
11/21
04:55
11/21/18
04:55
Recommendations
Analog Devices analyst commentary  »

Analog Devices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 11/17 Jobless…

ELEZY

Endesa

$0.00

(0.00%)

04:55
11/21/18
11/21
04:55
11/21/18
04:55
Conference/Events
Endesa to hold a webcast »

Strategic plan update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Leading Indicators to be reported at 10:00 »

October Leading…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

Week of 11/16 MBA…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

Week of 11/16 EIA…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

Week of 11/16 EIA Natural…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

October Durable Goods…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
Conference/Events
JPMorgan to hold a conference »

Best of British…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

Week of 11/21…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Durable Goods Orders to be reported at 08:30 »

October Durable Goods…

BBU

Brookfield Business Partners

$34.63

-1.71 (-4.71%)

04:55
11/21/18
11/21
04:55
11/21/18
04:55
Conference/Events
Brookfield Business Partners management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

04:55
11/21/18
11/21
04:55
11/21/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

October Existing Home…

GLW

Corning

$30.84

-0.31 (-1.00%)

, T

AT&T

$29.41

-0.93 (-3.07%)

04:55
11/21/18
11/21
04:55
11/21/18
04:55
Conference/Events
UBS optical/networking equip analyst to hold analyst/industry conference call »

Optical & Networking…

GLW

Corning

$30.84

-0.31 (-1.00%)

T

AT&T

$29.41

-0.93 (-3.07%)

VZ

Verizon

$59.46

-1.17 (-1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 03

    Dec

03:00
11/21/18
11/21
03:00
11/21/18
03:00
General news
FX Action: USD-CAD has steadied »

FX Action: USD-CAD has…

02:35
11/21/18
11/21
02:35
11/21/18
02:35
General news
FX Update: The Dollar majors have traded mixed »

FX Update: The Dollar…

02:00
11/21/18
11/21
02:00
11/21/18
02:00
General news
FX Action: USD-JPY has traded moderately firmer »

FX Action: USD-JPY has…

01:45
11/21/18
11/21
01:45
11/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

MDT

Medtronic

$92.31

1.91 (2.11%)

20:48
11/20/18
11/20
20:48
11/20/18
20:48
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic in the midst of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

RDY

Dr. Reddy's

$36.48

1.19 (3.37%)

20:44
11/20/18
11/20
20:44
11/20/18
20:44
Hot Stocks
Dr. Reddy's announces favorable outcome in Buprenorphine and Naloxone litigation »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.